Piecing together the Alzheimer's puzzle: Lecanemab's role in treatment

References

• 1. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int. J. Nanomed. 14, 5541–5554 (2019).
  Medline CASGoogle Scholar
• 2. Association AS. 2018 Alzheimer's disease facts and figures. Alzheimer's Dement. 14(3), 367–429 (2018).
  Google Scholar
• 3. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harbor Perspect. Med. 2(10), 1–2 (2012).
  Google Scholar
• 4. Lambert J-C, Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr. Opin. Gene. Develop. 21(3), 295–301 (2011).
  Medline CASGoogle Scholar
• 5. Giri M ZM, Lü Y. Genes associated with Alzheimer's disease: an overview and current status. Dovepress doi: https://doi.org/10.2147/CIA.S105769 (2016).
  Google Scholar
• 6. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622–630 (1988).
  Medline CASGoogle Scholar
• 7. Chen JX, Yan SS. Role of mitochondrial amyloid-beta in Alzheimer's disease. J. Alzheimer's Dis.: JAD 20(Suppl. 2), S569–S578 (2010).
  MedlineGoogle Scholar
• 8. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet. 19(R1), R12–20 (2010).
  Medline CASGoogle Scholar
• 9. Walsh S, Merrick R, Richard E, Nurock S, Brayne C. Lecanemab for Alzheimer's disease. BMJ 379, 3010 (2022).
  MedlineGoogle Scholar
• 10. Couzin-Frankel J, Piller C. Alzheimer's drug stirs excitement-and concerns. Science 378(6624), 1030–1031 (2022).
  Medline CASGoogle Scholar
• 11. Van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in early Alzheimer's disease. N. Engl. J. Med. 388(1), 9–21 (2023).
  Medline CASGoogle Scholar
• 12. Legleiter J, Czilli DL, Gitter B, Demattos RB, Holtzman DM, Kowalewski T. Effect of different anti-A–beta antibodies on A–beta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335(4), 997–1006 (2004).
  Medline CASGoogle Scholar
• 13. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl Acad. Sci. USA 93(1), 452–455 (1996).
  Medline CASGoogle Scholar
• 14. Lord A, Gumucio A, Englund H et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 36(3), 425–434 (2009).
  Medline CASGoogle Scholar
• 15. Swanson CJ, Zhang Y, Dhadda S et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's Res. Ther. 13(1), 80 (2021).
  Medline CASGoogle Scholar
• 16. Söllvander S, Ekholm-Pettersson F, Brundin RM et al. Increased number of plasma B cells producing autoantibodies against Aβ42 protofibrils in Alzheimer's disease. J. Alzheimer's Dis.: JAD 48(1), 63–72 (2015).
  MedlineGoogle Scholar
• 17. Tucker S, Möller C, Tegerstedt K et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J. Alzheimer's Dis.: JAD 43(2), 575–588 (2015).
  Medline CASGoogle Scholar
• 18. Magnusson K, Sehlin D, Syvänen S et al. Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain. J. Alzheimer's Dis.: JAD 37(1), 29–40 (2013).
  Medline CASGoogle Scholar
• 19. Söderberg L, Johannesson M, Nygren P et al. Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease. Neurotherapeutics 20(1), 195–206 (2023).
  MedlineGoogle Scholar
• 20. Rentería ME, Mitchell BL, De Lara AM. Genetic testing for Alzheimer's disease: trends, challenges and ethical considerations. Curr. Opin. Psychiatry 33(2), 136–140 (2020).
  MedlineGoogle Scholar